Navigation Links
New test to study proteins involved in neurodegenerative diseases
Date:2/2/2011

Researchers from the Institute of Biotechnology and Biomedicine and the UAB Department of Biochemistry and Molecular Biology have developed and patented a method using Saccharomyces cerevisiae yeast to detect in human proteins the formation of oligomers, small toxic aggregations of molecules which can initiate the assembly of amyloid fibres found in neurodegenerative diseases. The test allows validating the efficacy of compounds which could dissolve or inhibit these aggregates, as well as studying at basic level the therapeutic potentiality of a large number of molecules.

Oligomers are formed by the union of two to twenty molecules. Recent research studies seem to indicate that their toxicity is higher than that of amyloid fibres. However, studying these substances is not easy given that they are unstable and their formations are transitory.

The method developed by researchers at UAB locates and monitors in vivo the aggregation process of the protein using fluorescence techniques and without the need to resort to alternative methods. It also allows studying compounds which inhibit oligomers as potentially therapeutic mechanisms to prevent posterior formations of amyloid plaques.

The screening system was carried out by genetically modifying Saccharomyces cerevisiae yeast to link human protein aggregation to cell death. It is based on the fusion of the human peptide under study with the human variant of a protein needed for the survival of the modified yeast, dihydrofolate reductase (DHFR). The aggregation of the peptide deactivates the DHFR protein and finally produces the death of the cell, thereby providing a detection system of molecules with tendency to aggregate and in which any compound capable of separating or inhibiting this aggregation would favour the survival of the cell.

Researchers carried out the study with the AB42 peptide, the main cause of Alzheimer's disease. To validate the test they worked with several compounds in vitro which, in studies related to the disease, had demonstrated to be effective against the formation of oligomers, amyloid fibres or both types of molecules. The system only showed to be effective with compounds affecting oligomers, which makes it a very specific method for the initial detection of the aggregation process. The system was also validated with chaperones, a group of proteins which increase the dissolution of protein aggregation and favour cell survival. In addition to AB42, researchers validated the assay with regard to the detection of initial aggregations, by using proteins involved in Parkinson's and Huntington's disease.

According to Salvador Ventura, one of the authors of the study, the system is easy to use and allows scientists to work quickly and to analyse with reliability the potential therapeutic efficacy of an infinite number of compounds at experimental level. Now there is the need to automate the system - with plates allowing for the simultaneous analysis of more than fifty molecules per assay - to be used in basic research. For the moment the system has been patented by the researchers.


'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Related biology technology :

1. A new model for studying Parkinsons
2. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
3. Columbia University researchers use nanoscale transistors to study single-molecule interactions
4. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
5. New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries
6. Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal
7. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
8. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
9. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
10. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
(Date:6/22/2016)... Philadelphia, PA (PRWEB) , ... June 22, 2016 ... ... the University City Science Center’s Port business incubator and current participant in the ... therapy and treatment for cancer patients. , Quantitative Radiology Solutions helps physicians ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):